About Us
Our Story
Team
Careers
News
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Select specialty
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Endocrinology
General Surgery
Hematology
Nephrology
Neurosurgery
Oncology
Oral Maxillofacial
Orthopaedics
Pediatrics
Plastic Surgery
Podiatry
Primary Care
Pulmonology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Confirm Password
Mohs Surgery for Melanoma - Techniques and Timing of Treatment
By
Melanoma 2019: 29th Annual Cutaneous Malignancy Update
FEATURING
Adam Sutton
February 2019
0 Comments
Login to view comments.
Click here to Login
Related Content
AUTOPLAY
ON
Scripps MD Anderson Cancer Center
Melanoma 2020: 30th Annual Cutaneous Malignancy Update
Sat, Jan 25, 2020
18th Annual South Beach Symposium
18th Annual South Beach Symposium
Thu, Feb 6, 2020
06:54
2019 Scripps MD Anderson's Oncology Update
ASCO 2019 Update on Tumor Infiltrating Lymphocyte Therapy for Metastatic...
Feat.
G. Daniels
19:20
Melanoma 2019: 29th Annual Cutaneous Malignancy Update
Pathology of Melanoma: Current Status and Prognostic Indicators
Feat.
D. Barnette
10:10
ANCO’s ASCO Highlights 2019
ASCO Update: NIVO + IPI - New First-Line Therapy for Asymptomatic Melano...
Feat.
K. Tsai
08:44
KU Hematology & Medical Oncology Review 2019
ASCO 2019 Long-Term Survival of Dabrafenib Plus Trametinib in Metastic B...
Feat.
G. Doolittle
12:20
Melanoma 2019: 29th Annual Cutaneous Malignancy Update
Do Dysplastic Nevi Progress to Melanoma?
Feat.
B. Kelley
18:28
Cleveland Clinic Taussig Cancer Institute
Kinase Inhibition for IMIDs: Biology of Kinases Targeting, Jak Inhibitio...
Feat.
W. Rigby
12:45
Yale Cancer Center
Metastatic Melanoma as a Model Disease for Immunotherapy, Advances in Im...
Feat.
H. Kluger
24:06
Melanoma 2019: 29th Annual Cutaneous Malignancy Update
Neoadjuvant Therapy for Advanced Resectable Nodal Metastases: Advantages...
Feat.
M. Ross
31:20
Melanoma 2019: 29th Annual Cutaneous Malignancy Update
Advanced/High Risk Melanoma: Therapies in Adjuvant Setting & Ongoing Cli...
Feat.
K. Bollin
30:53
Melanoma 2019: 29th Annual Cutaneous Malignancy Update
Updates on Systemic Therapy for High Risk & Advanced Melanoma with Case ...
Feat.
K. Bollin
12:59
Melanoma 2019: 29th Annual Cutaneous Malignancy Update
Melanoma, the Primary Lesion: Biopsy, Excision and Mohs Surgery in Selec...
Feat.
A. Sutton
24:23
Cleveland Clinic Orthopaedic & Rheumatologic Institute
Autoimmune Complications from Cancer Chemotherapy: An Emerging Field
Feat.
L. Cappelli
22:33
Melanoma 2019: 29th Annual Cutaneous Malignancy Update
Melanoma: Head and Neck Melanoma Workup, Review of SEER Melanoma Margin ...
Feat.
C. Bergeron
30:59
Melanoma 2019: 29th Annual Cutaneous Malignancy Update
Metastatic Evaluation after Melanoma Treatment Including the Risk of a S...
Feat.
D. Zelac
10:14
2019 Scripps MD Anderson's Oncology Update
ASCO 2019 Update on Dabrafenib and Trametinib in BRAF Metastatic Melanom...
Feat.
G. Daniels
15:52
Yale Cancer Center
Immune Therapy Combinations for Melanoma Tumors Resistant to PD-1 Inhibi...
Feat.
H. Kluger
07:50
KU Hematology & Medical Oncology Review 2019
ASCO 2019 Updates on Trial Discussing Nivolumab + Ipilimumab in Melanoma...
Feat.
G. Doolittle
13:33
Cleveland Clinic Taussig Cancer Institute
Targeted Therapy of Melanoma: Where Are We Going?
Feat.
P. Funchain
22:58
Dana-Farber Cancer Institute
Identification and Management of Toxicities Related to Immunotherapy for...
Feat.
O. Rahma
20:31
Cleveland Clinic Taussig Cancer Institute
Update in Molecular Diagnostics for Melanoma Cutaneous Malignancies
Feat.
S. Billings
